Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension

Thorax

Volumn 67, Issue 11, 2012, Pages 977-984

  Stefan, Mihaela S ^a,b,c   Rothberg, Michael B ^a,b,c   Priya, Aruna ^d   Pekow, Penelope S ^a,d   Au, David H ^e   Lindenauer, Peter K ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLXANTHINE DERIVATIVE; METOPROLOL; PROPRANOLOL; WARFARIN;

ACUTE DISEASE; ADULT; AGED; ANGIOGRAPHY; ARTERIAL GAS; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84868198047     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-201945     Document Type: Article

References (28)

1. Wier LM, Elixhauser A, Pfuntner A, et al. Overview of hospitalizations among patients with COPD, 2008: statistical brief #106. Feb. 2011. In: Healthcare Cost and Utilization Project (HCUP) statistical briefs [Internet]. Rockville, MD: Agency for Health Care Policy and Research, USA. Feb. 2006. http://www.ncbi.nlm.nih.gov. ezproxy. library.tufts.edu/books/NBK53969
2. NHLBI Morbidity and Mortality Chartbook. http://www.nhlbi.nih.gov/ resources/docs/cht-book.htm (accessed 1 Jun. 2011).
3. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002;121:846-51. (Pubitemid 34251453)
4. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998;114:411-15. (Pubitemid 28387516)
5. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996;154:1598-602. (Pubitemid 26424921)
6. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90.
7. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54:2205-41.
8. Lammers JW, Folgering HT, Van Herwaarden CL. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. Br J Clin Pharmacol 1985;20:205-10. (Pubitemid 15228370)
9. Van der Woude HJ, Zaagsma J, Postma DS, et al. Detrimental effects of betablockers in COPD: a concern for nonselective beta-blockers. Chest 2005;127:818-24. (Pubitemid 40775510)
10. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; (4): CD003566.
11. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003;97:1094-101. (Pubitemid 37185112)
12. Stefan MS, Bannuru RR, Lessard D, et al. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a ten-year retrospective observational study. Chest 2012;141:1441-8.
13. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97. (Pubitemid 28384881)
14. Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005;98:493-7. (Pubitemid 41418672)
15. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2009;137:1091-7.
16. Lindenauer PK, Pekow PS, Lahti MC, et al. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010;303:2359-67.
17. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27. (Pubitemid 128456396)
18. Johnston SC, Henneman T, McCulloch CE, et al. Modeling treatment effects on binary outcomes with grouped-treatment variables and individual covariates. Am J Epidemiol 2002;156:753-60. (Pubitemid 35155182)
19. Brooks TW, Creekmore FM, Young DC, et al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007;27:684-90. (Pubitemid 46700960)
20. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7.
21. Au DH, Bryson CL, Fan VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 2004;117:925-31. (Pubitemid 40075560)
22. Dransfield MT, Rowe SM, Johnson JE, et al. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008;63:301-5. (Pubitemid 351497940)
23. Suissa S, Ernst P. Biases in the observational study of beta blockers in COPD. Thorax 2008;63:1026-7; author reply 1027.
24. Camsari A, Arikan S, Van C, et al. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003;18:188-92. (Pubitemid 37258672)
25. Chang CL, Mills GD, McLachlan JD, et al. Cardio-selective and non-selective betablockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Intern Med J 2009;40:193-200.
26. Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990;263:1653-7. (Pubitemid 20090694)
27. Teichert M, de Smet PA, Hofman A, et al. Discontinuation of beta-blockers and the risk of myocardial infarction in the elderly. Drug Saf 2007;30:541-9. (Pubitemid 46873079)
28. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J 2001;141:148-53. (Pubitemid 32061325)